Vaccinex Inc Stock Price, News & Analysis

Vaccinex, a clinical-stage biotechnology firm, reported progress on its clinical programs for pepinemab, a SEMA4D inhibitor. The Phase 1b/2 KEYNOTE B84 study with KEYTRUDA® in head and neck cancer shows promising initial responses, with confirmed complete responses observed in patients with low PD-L1 expression. Financially, Vaccinex reported a net loss of $4.8 million for Q3 2022, a slight decrease from the previous year. The company aims to meet with the FDA regarding the use of HD-CAB as a potential surrogate endpoint to accelerate the approval process for Huntington's Disease treatment.

Vaccinex Inc. (Nasdaq: VCNX) announced promising findings regarding its drug pepinemab at the SITC 37th Annual Meeting. Two studies highlighted the drug's potential when combined with immunotherapy for treating Stage III melanoma and HER2+ metastatic breast cancer. Results showed a remarkable 100% recurrence-free rate after 24 months for patients treated with a triple combination of pepinemab, nivolumab, and ipilimumab. The findings underline the importance of biomarkers in determining treatment efficacy and the drug's capacity to enhance immune responses. Vaccinex is also pursuing further studies, including a Phase 1b/2 trial.

Vaccinex, a clinical-stage biotech focused on cancer and neurodegenerative diseases, reported promising initial responses in the Phase 1b/2 KEYNOTE B84 study of pepinemab combined with KEYTRUDA® for advanced head and neck cancer. They also published results from the Phase 2 SIGNAL study in Huntington's Disease in Nature Medicine, showing potential cognitive benefits despite not meeting primary endpoints. Financially, Vaccinex reported $11.4 million in cash and equivalents, with a net loss of $5.4 million for Q2 2022, an improvement from $6.0 million in Q2 2021.

Vaccinex, Inc. (VCNX) has released findings from its Phase 2 SIGNAL trial, showcasing the potential of its SEMA4D-blocking antibody, pepinemab, to address cognitive decline in Huntington’s Disease (HD). Although the primary efficacy endpoints were not met, significant reductions in brain atrophy and preservation of metabolic activity were reported. Furthermore, the article published in Nature Medicine highlights cognitive improvements, especially in patients with early symptoms. The company is initiating a Phase 1b/2a study for Alzheimer's Disease, suggesting broader implications for neurodegenerative treatments.

Vaccinex, Inc. (Nasdaq: VCNX) announced its selection for a poster presentation at the 2022 Alzheimer’s Association International Conference, scheduled from July 31 to August 4 in San Diego. The presentation will focus on pepinemab, its innovative treatment for Alzheimer’s Disease, which targets SEMA4D. The ongoing Phase 1/2a SIGNAL-AD study aims to evaluate the safety and effects of pepinemab in early-stage Alzheimer’s patients. The study is partially funded by the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association.

Vaccinex, Inc. (Nasdaq: VCNX) announced that Dr. Maurice Zauderer and Dr. Elizabeth Evans will present at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 a.m. ET. They will update investors on progress in phase 2 trials for their lead product, pepinemab, targeting head and neck cancer and Alzheimer’s disease. One-on-one meetings will occur from June 8 to 10. Pepinemab aims to inhibit SEMA4D to prevent immune infiltration in tumors and inflammation in chronic brain diseases, with ongoing studies for Huntington’s disease development.

Vaccinex, Inc. (Nasdaq: VCNX) announced promising results from its clinical trial of pepinemab in combination with KEYTRUDA for treating recurrent/metastatic head and neck cancer, noting two complete responses among the first three patients. The Phase 1b/2 KEYNOTE-B84 trial has 65 planned participants. Additionally, enrollment is ongoing for the SIGNAL-AD trial in early Alzheimer’s disease. Financially, Vaccinex reported cash equivalents of $16.8 million as of March 31, 2022, with a net loss of $4.6 million for the quarter, an improvement from $6.6 million the previous year.

Vaccinex, Inc. (Nasdaq: VCNX), a biotechnology firm focused on cancer and neurodegenerative disease therapies, announced its selection for a poster presentation at the 18th Annual PEGS Boston Conference from May 2-6, 2022. The presentation will showcase their ActivMAb technology, which enables efficient expression of complex transmembrane receptors critical for drug discovery. This groundbreaking platform successfully identifies antibodies against targets like SARS-CoV2 and chemokine receptor CXCR4. Details will be accessible on their website starting May 2 at 3:50 PM EST.

Vaccinex, Inc. (Nasdaq: VCNX) reported positive developments in its ongoing clinical trials for pepinemab in oncology and neurodegenerative diseases. The Phase 1b segment of the KEYNOTE-B84 study in head and neck cancer showed two complete responses among three initial patients. Enrollment is ongoing for both the KEYNOTE-B84 and SIGNAL-AD trials, with topline data expected in 2023. Financially, Vaccinex ended 2021 with $8.6 million in cash, reflecting a decrease from $10.6 million in 2020. The comprehensive loss for 2021 was $22.4 million, an improvement from $28.9 million in the previous year.